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                                                       ABSTRACT 
 
Background: 
Periodontitis is a multifactorial infectious disease characterized by gingival  
inflammation  and attachment loss in susceptible host. Several  biochemical events  that 
occur during inflammation  leads to release  of various enzymes by  plaque bacteria and  
host  tissue  cells .Of such  various  enzymes, the host  lysosomal  cysteine proteases  
like  cathepsin  B,H,L are currently thought to be major contributors of  periodontal 
tissue destructions .                
Cystatin C is a  part of super family of cysteine protease inhibitors. It is a 
nonglycosylated , basic, low molecular  weight  protein  widely distributed  in biological 
fluids. It regulates the inflammatory periodontal disease by inhibiting the collagen 
degrading  cathepsin and play a pivotal  role in tissue remodelling by down regulating 
proteases activity. Thus it may serve as a useful biochemical marker for assessing  
periodontal disease status .Many studies have been carried out till date that talk about the 
severity of chronic periodontitis and aggressive periodontitis but none correlates with 
Cystatin C level in blood. 
Aim :To determine and compare the levels of   serum Cystatin C before and after phase 
1 therapy in patients with chronic periodontitis and  aggressive periodontitis. 
Methods: A total of 30 subjects were selected, 10 each of generalised chronic 
periodontitis, generalised aggressive periodontitis and healthy (control group).Blood 
sample was collected and serum  Cystatin C value  was detected from all subjects at 
baseline and 3 months after phase 1 therapy. Clinical  parameters such as plaque index , 
gingival bleeding index, probing pocket depth, clinical attachment level were recorded at 
baseline and at 3 months after phase 1 therapy . 
Results: There was significant correlation  between the baseline value of clinical 
parameters and  serum Cystatin C level in healthy ,chronic and aggressive periodontitis  
patient. Statistically  significant reduction was observed in the serum Cystatin C level in 
both chronic periodontitis and aggressive periodontitis patients 3 months after phase I 
therapy as compared to baseline level. 
Conclusion : 
Within the  limitations  of the present study, it can be concluded  that  serum Cystatin C 
concentration was found to be elevated from periodontally healthy group to chronic 
periodontitis group and aggressive periodontitis  and decrease in after periodontal 
therapy group. This suggests that Cystatin C acts as anti-inflammatory marker in  serum. 
 
 
Keywords: Periodontitis, Serum Cystatin C, Phase 1  therapy  
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INTRODUCTION 
    Periodontitis is a chronic infectious disease, triggered by the host immune 
response to an array of periodontal biofilm-associated microorganisms, which 
ultimately leads to the inflammation of the tissues supporting the teeth. 
    The initial host response to bacterial infection is a local inflammatory 
reaction that activates the innate immune system. An imbalance between biofilms and 
immune system results in over expression of an array of pro-inflammatory cytokines, 
propagation of inflammation through the gingival tissues and subsequent destruction 
of alveolar bone. Thus, the inflammatory process results in destruction of connective 
tissue and alveolar bone  is considered as Hallmark of periodontal disease. 
     Diagnosis of periodontal disease has been primarily based upon clinical and 
radiographic measures of periodontal tissue destruction. These parameters provide a 
measure of past destruction and are of limited use in early diagnosis 
1
 . Biomarkers of 
disease play an important role in life sciences and have begun to assume a greater role 
in diagnosis, monitoring of therapy outcomes, and drug discovery 
2
. For biomarkers to 
assume their rightful role in routine practice, it is essential that their relation to the 
mechanism of disease progression and therapeutic intervention be more clearly 
understood. 
                Most of the charecteristics of periodontal disease such as inflammation and 
attachment loss are associated with proteolytic events .Biochemical events  that occur 
during inflammation  leads to release  of various enzymes by  plaque bacteria and  
host  tissue  cells .Of such  various  enzymes, the host  lysosomal  cysteine proteases  
like  cathepsin K ,cathepsin B,cathepsin H,cathepsin L are currently thought to be 
major contributors of  periodontal tissue destructions 
3 .
 
              Cystatins are inhibitors of cysteine proteinases . It  could play a protective 
and regulatory role under inflammatory conditions..Cystatin C (CSTC), also known as 
INTRODUCTION 
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γ-trace (Gamma trace) or post γ globulin protein belongs to family 2 of the Cystatin 
superfamily ..The synthesis of Cystatin C does not seem to be tissue-specific and all 
nucleated cells  constitutively express and constantly secrete Cystatin C  
4
. 
       It regulates the inflammatory periodontal disease by inhibiting the 
collagen degrading  cathepsin and play a pivotal  role in tissue remodelling by down 
regulating proteases activity
5
. Thus it may serve as a useful biochemical marker for 
assessing  periodontal disease status . 
                   Anuj Sharma et al ,reported that  Cystatin  C concentration in  GCF and 
serum were  increased  proportionally with the severity of  periodontal  disease (from 
health to periodontitis group) and decreased after treatment 
6
.  Graziani F et al 
reported that ,serum   Cystatin C level was significantly  decreased  after  non surgical  
therapy in  generalised  chronic periodontitis  patients
7
.  
         Chronic and aggressive forms of periodontitis show disparity in the rate 
of disease progression. Cystatin C levels in chronic and aggressive periodontitis seems 
to be an appealing area of research. Thus, the present study was undertaken to 
estimate  the levels of serum Cystatin C  in  healthy individuals chronic and 
aggressive periodontitis patients  and subsequently  3 months after phase 1 therapy in 
chronic and aggressive periodontitis patients .And  also  to  compare and correlate  the 
serum levels of  Cystatin C in aggressive and chronic periodontitis patients with the 
severity of periodontal disease.. 
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AIM 
 The aim of this study is to determine and compare the levels of   serum 
Cystatin C before and after phase 1 therapy in –  
-patients with chronic periodontitis  
- patients with aggressive periodontitis 
-Healthy  group (control group) 
 
OBJECTIVES 
1. To evaluate the clinical parameters 
 At baseline in healthy patients   
 At baseline and 3 months after phase 1 therapy in patients with 
chronic periodontitis  
 At baseline and 3 months after phase 1 therapy in patients with 
aggressive periodontitis  
2. To evaluate  serum Cystatin C level 
 At baseline in healthy patients 
 At baseline and 3 months after phase 1 therapy  for   patients   with 
chronic periodontitis  
 At baseline and 3 months after phase 1 therapy  for patients with 
aggressive periodontitis 
3. Correlate the clinical parameters and serum Cystatin C levels in each group 
before and after phase 1 therapy. 
4. Compare the clinical parameters and serum  Cystatin C levels between groups 
before and after phase 1 therapy. 
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REVIEW OF LITERATURE 
    Periodontal disease is characterized by tissue inflammation and destruction 
of the tooth supporting structures that eventually leads to the loss of affected teeth 
(Kinane 2001, Page & Kornman 1997, Philstrom et al. 2005)
7,8,9 .
. 
                Despite our increased understanding of the etiology and pathogenesis of 
periodontal infections, the diagnosis of these diseases is still based almost entirely on 
traditional clinical assessment ( Armitage 1995)
10
. To arrive at a periodontal 
diagnosis, the dentist must rely upon factors such as 
     (a) presence and absence of signs and symptoms, including pain, ulceration and 
amount of observable plaque and calculus 
     (b) patients medical and dental history  
    (c) presence or absence of clinical signs of inflammation like bleeding on probing  
    (d) probing depths and 
    (e) extent and pattern of clinical attachment and bone loss.  
                      These parameters provide a measure of past destruction and are of 
limited use in early diagnosis (Frodge et al,2008)
1
. Because of the increasing 
prevalence and associated comorbidities, screening and diagnostic modalities for the 
early identification of periodontitis, its initiation and progression, as well as objective 
measures for response to therapy, are being sought. ( Beck et al 2005, Genco et al 
2001, Seymour et al 2007, Mealey & Oates 2006 )
11,12,13,14
. 
BIOMARKERS ; 
                         A periodontal diagnostic tool should  provide  information for 
differential diagnosis, localization of disease, and severity of infection. These 
diagnostics, in turn, serve as a basis for treatment planning  and provide a means for 
assessing the effectiveness of periodontal therapy (Taba et al 2005)
15
. In the disease 
 REVIEW  OF  LITERATURE 
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process, potential biomarkers of the disease activity would need to be involved in 
some way in the disease process or released as a consequence of tissue damage during 
disease progression. 
                    A biomarker is an objective measure that has been evaluated and 
confirmed either as an indicator of physiologic health, a pathogenic process, or a 
pharmacologic response to a therapeutic intervention.  
Cystatins; 
                   The Cystatins are the reversible competitive inhibitors of C1 cysteine 
proteases. Cystatins interact with the mammalian cathepsins, B, H and L.  
The Cystatins superfamily that can be categorized into three major families.( Hensken 
et al1996)
16
. 
  1)Family 1- Stefins (stefin A and B; also known as Cystatin A and B)  
                      They are unglycosylated inhibitors of ~11 kDa, lack signal sequence and 
disulfide bonds and are generally expressed intracellularly. 
 2) Family 2 (Cystatins) Cystatin C, D, S, SA, and SN 
                      They are glycosylated,and molecular masses in the range of 13–14 kDa, 
contain signal sequence and disulfide bonds at the carboxy terminus of the 
molecule.they are  expressed  extracellularly .mainly found in secretory fluid  and are 
represented in saliva by acidic (S,SA),neutral (SN,D),basic (C) Cystatins. 
3) Family 3 (kininogens) 
                  They   have molecular weights in the range of 88–114 kDa, are 
glycosylated . 
have three family-2 Cystatin domains, two of which (domains 2 and 3) have protease 
inhibitory activities  
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HISTORY OF CYSTATIN C  
 Cystatin C was first described as 'gamma-trace' in 1961 as a trace protein 
together with other ones (such as beta-trace) in the cerebrospinal fluid and in 
the urine of patients with renal failure. In 1995 Grubb and Löfberg first reported its 
amino acid sequence.
17
. 
structure of Cystatin 
Cystatins  form a wedge-shaped structure that blocks the active site of C1 
cysteine proteases
18
 .There are an N-terminal glycine, a glutamine valine-glycine (Q-
X-V-X-G) loop and a second c-terminus hairpin loop consisting of prolinetyptophan 
(PW) residues .It should, however, be noted that in human stefins, the PW motif is 
replaced by PG in stefin A and PH in stefin B. These conserved residues are also 
reflected in the ClustalW alignment 
19
 of the amino acid sequences of the family-2 
Cystatins. 
Cystatin C is a non-glycosylated, basic protein (isoelectric point at ph 9.3). 
The crystal structure of Cystatin C is characterized by a short alpha helix and a long 
alpha helix which lies across a large antiparallel, five-stranded beta sheet. Like other 
type 2 Cystatins, it has two disulfide bonds. Around 50% of the molecules carry 
a hydroxylated proline. Cystatin C forms dimers (molecule pairs) by exchanging 
subdomains; in the paired state, each half is made up of the long alpha helix and one 
beta strand of one partner, and four beta strands of the other partner.( Grubb A et al 
1982 )
17 
. 
Cystatin encoding genes; 
The Cystatin locus on the short arm of chromosome 20 contains the majority 
of the type 2 Cystatin genes and pseudogenes.The CST3 gene is located in the 
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Cystatin locus and comprises 3 exons (coding regions, as opposed to introns, non-
coding regions within a gene), spanning 4.3 kilo-base pairs. It encodes the most 
abundant extracellular inhibitor of cysteine proteases. It is found in high 
concentrations in biological fluids and is expressed in virtually all organs of the body 
(CST3 is a housekeeping gene). The highest levels are found in semen, followed 
by breast milk, tears and saliva. The hydrophobic leader sequence indicates that the 
protein is normally secreted. There are three polymorphisms in the promoter region of 
the gene, resulting in two common variants (Hwang SJ, et al (2007 )
20
.Several single 
nucleotide polymorphisms have been associated with altered Cystatin C levels.( 
Janowski R  et al 2001
) 21
. 
LABORATORY MEASUREMENT ; . Newman DJ  2003 
Cystatin C can be measured in a random sample of serum  using  
1.Enzyme Linked Immuno assays  
2. nephelometry  
3. particle-enhanced turbidimetry 
Normal range of Cystatin levels in serum --0.57-1.12 mg/l 
22 
Cystatin C in  pathological conditions; 
A  number of studies have suggested an inverse relationship between the stage 
of tumor progression and the levels of Cystatins in the tumor microenvironment. As 
tumors progress towards the metastatic end stage, the levels of the Cystatins in both 
the cytosol and extracellular spaces are drastically reduced.( 2003 Kothapalli R, 
Korolenko TA)
23,24
. 
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Sokol et al.2004  identified Cyst C as a novel antagonist of TGF-β signaling.29. 
They determined that Cyst C physically interacts with TGF-β receptor II, thereby 
abrogating the binding of TGF-β. It is known that TGF-β has growth suppressing 
properties, particularly in normal epithelial cells,
25,26
. 
Cystatins in stabilization of MMP; 
Matrix metalloproteinases (MMPs) are homologous Zn2+-dependent 
proteinases that  participate in the physiological and pathological processes, which 
require tissue remodelling(.1990Matrisian LM)
27 
. Their expression profiles are highly 
regulated and defects in their regulatory pathways are  likely to give rise to diseases 
ranging from cancer, arthritis, and cardiovascular disorders to periodontal diseases.( 
Coussens LM1996, Rudolph-Owen LA, 1998, Walakovits LA,1992, Dollery 
CM1995
) 28,29,30,31. 
Cystatin superfamily can stabilize and protect matrix metalloproteinases 
without affecting their activities towards their natural substrates, such as gelatin  (Ray 
S,2003)
32
. 
Cystatins –new marker of GFR; 
Simonsen et al.1985, first noted the excellent correlation between Cyst C 
secretion and GFR when compared with the gold standard exogenous markers of 
GFR, such as  Cr-EDTA
33
. Cyst C is present in high concentrations in serum, saliva, 
and seminal, synovial, and cerebrospinal fluids
34
. It is produced and secreted at a 
constant rate by most nucleated cells and is freely filtered by the glomerular because 
of its small size. Unlike creatinine, serum CYSTATIN  C is not secreted by renal 
tubular epithelial cells, although they reabsorb and catabolyze it so that Cyst C does 
not return to the bloodstream. (Reed CH 2000).
35
. 
 
 REVIEW  OF  LITERATURE 
 
9 
 
Immunomodulatory Properties of Cystatins: 
During inflammatory processes, Cystatin C release is down-regulated, 
contributing to increased cysteine protease activities in the macrophage 
microenvironment. (Chapman HA Jr, 1990)
36
. Cyst C is a powerful inhibitor of 
cathepsins S and L. High levels of Cyst C are detectable in class II-positive lysosomes 
of immature dendritic cells (DCs) and Langerhans cells. The maturation process of 
DCs leads to reduced levels of cyst C, and allows the up-regulation of cysteine 
proteases cathepsins L and S. For this reason, it has been suggested that Cyst C plays a 
role in the intracellular control of invariant chain (li) degradation and antigen 
presentation. (Pierre P,1998)
37
. Members of the three Cystatin families have been 
shown to up-regulate the release of nitric oxide (NO) from IFN-gamma activated 
macrophages (Verdot L,1996, Hartmann S,2002,)
38,39
. NO has been demonstrated to 
induce a strong inhibition of lymphocyte proliferation in vitro and to modulate 
cytokine gene expression in various cell type.(Marletta 1993)
40
. It is important to note 
that Cystatin induced up-regulation of NO release by activated macrophages is 
stimulated via the synthesis of TNF-alpha and IL-10 .( Kolb.H. 1992)
41
. 
Cystatin C  in medical conditions: 
Cystatin C  has been associated with various diseases with chronic 
inflammation 
42 
and atherosclerosis (J. Leung-Tack 1990)
43
, new onset hypertension ( 
B. Kestenbaum2008,)
44
, tumors( P. Strojan 2004)
45
, thyroid dysfunction [V. 
Jayagopal, B.G 2003]
46 and Alzheimer’s disease ( E. Levy 2001.)47 . 
In  2007 Bokarewa M, et al   assayed Cystatin C  in the serum of patients with 
rheumatoid arthritis by ELISA and it was hypothesized that decreased systemic 
Cystatin C levels predispose to accelerated atherosclerosis and development of 
amyloidosis in patients with the rheumatoid arthritis .
48 
.In 2007  Tanaka et al.  found 
 REVIEW  OF  LITERATURE 
 
10 
 
that  Cystatin C is a serum marker of renal function in both healthy and diseased 
patients.
42
. 
Cystatin C in periodontal disease; 
In 1989 Ska-leric et al.conducted a study consist of Gingival tissue samples 
were obtained during periodontal surgery from 22 patients with different degrees of 
inflammatory periodontal disease, as indicated by gingival index and probing depth 
(PD). The amount of the low molecular-weight inhibitor, Cystatin C, was determined 
by the enzyme-linked immunosorbent assay, The concentration of Cystatin C was in 
the range from 0.21 to 3.82 μg/g tissue .and they concluded that Cystatin C was 
significantly decreased (p<0.01) in samples taken from sites with increased PD.
49
. 
In 1990  Leung-Tack et al reported that Cystatin C has a regulatory role in 
inflammatory process by down regulation of phagocytosis associated respiratory burst  
reaction displayed by polymorphonuclear neutrophils and by down regulation of their 
chemotactic activity. 
43
 
In 1991 Warfel et al  reported that alveolar macrophages from smokers 
secreted more Cystatin C in in-vitro cultures than such cells from non-smokers.
50
.                  
In 1992 Aguirre et al found that  no differences were observed in the salivary 
concentrations of Cystatins S, SA and SN between periodontal patients and healthy 
controls 
51. 
 In 1993 Lah et al, reported that the concentration of Cystatin C in gingival 
tissue samples obtained from patients at various stages of periodontitis was 
significantly decreased when taken from sites with increased probing depths.
52
                         
In 1994  Henskens et al.  found no CSTC  levels in GCF samples while 
increased concentrations of CSTC were detected in whole saliva in both gingivitis and 
periodontitis subjects in comparison with healthy subjects.
53
 . 
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In 1996 Henskens et al.  found the main Cystatin members of family 2 are 
Cystatin C, D, S, SA and SN,  in secretory fluids, including saliva 
54,55.
 . 
In 1998 Schick C.et al reported that  Cystatin C is an anti-inflammatory factor 
and decreases the secretion of cathepsin K, which is cysteine protease that plays an 
important role in bone loss especially in the alveolar bone.
56
. 
In 1999 baron et al showed that Cystatins play a role in complex process of 
periodontal diseases and  salivary Cystatin in whole saliva provide a useful tool in 
monitoring periodontal disease  status.
57
. 
In 2000  Finney et al, Cystatin C is within a range of 0.51–0.98 mg/l  in the 
absence of renal disease 
58. . 
In 2001 Lie et al.showed  no significant changes in salivary Cystatin activity 
and the Cystatin C concentration after 2 weeks of experimental gingivitis
.59
. 
In 2002 Laterza et al. showed that Cystatin C is not influenced by age,muscle 
mass or sex 
60
. 
In 2003 Gills et al concluded that  no significant changes occur in salivary 
Cystatin activity and Cystatin C concentration during and after experimental 
gingivitis.
61
               
 
           In 2005   Yamaza T et al  showed that  Cystatin C was demonstrated 
within the junctional epithelium of rat gingiva using immunohistochemistry with 
light and electron microscopy.
62
. 
 In 2006  Shlipak et al considered that  GFR may be accurately measured 
using Cystatin C serum levels 
63
. 
 In 2008  A.E. Ulker,et al showed that decreased levels of CSTC  in 
gingival crevicular fluid (GCF) and total saliva in children with gingivitis 
compared to periodontally healthy children 
64
.            . 
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  In 2009 C.H. Tsai, S.F. Yang,  et al reported that Periodontal pathogens 
[Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans (now known as 
Aggregatibacter actinomycetemcomitans)] and proinflammatory cytokines when 
added to gingival fibroblast induced by cyclosporine A, significantly increases the 
expression of CSTC compared with cyclosporine A alone 
65
. 
In 2010 . Graziani F et al. did the study about  Effects of non-surgical 
periodontal therapy on the glomerular filtration rate of the kidney using using ,  serum 
Cystatin C marker.and he concluded  substantial reduction in serum CSTC 
concentration after non surgical periodontal therapy and  Cystatin C levels, may be 
positively affected by Periodontal therapy
66
. 
Anuj Sharma et al 2012 did the study to assess the concentration of CSTC in 
gingival crevicular fluid (GCF) and serum, to find out their association , in periodontal 
health and disease and he  concluded that   CSTC  concentration in GCF and serum 
increased proportionally with the severity of periodontal disease (from health to 
periodontitis  group) and decreased after treatment 
5..
. 
In 2014 Aditishrikrishnadhage et al concluded that Cystatin C in saliva can be 
considered as a potent inflammatory biomarker to assess periodontal disease severity 
and its markedly low levels in aggressive periodontitis 
67
.In 2018   the same 
conclusion was explained in research gate(Anuj Sharma et al)
5
. 
Within this context Cystatin C represents an emerging and reliable marker of  
inflammation of periodontium . ,measurement of which contributes to  monitor the 
response to treatment of inflammation and infection . 
 Phase 1 Periodontal therapy; 
 Treatment of periodontitis is directed primarily towards the reduction of 
pathogens embedded in the subgingival biofilm..The primary goal of periodontal 
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therapy is to preserve the natural dentition by achieving and maintaining a healthy 
functional periodontium. It consists of patient motivation and oral hygiene 
instructions as well as mechanical removal of supra and subgingival plaque and 
calculus deposits, correction of plaque-retentive factors (eg. overhangs) and risk 
factor modification (eg. smoking cessation). Many terms have been used to 
describe this process such as nonsurgical periodontal therapy, initial periodontal 
therapy, hygiene phase therapy, mechanic therapy and cause-related periodontal 
therapy. 
 Non-surgical periodontal therapy include scaling and root planing to 
remove bacterial plaque and calculus subgingivally by mechanical means, using 
either manual instruments such as hand scalers/curettes or machine-driven 
instruments such as sonic or ultrasonic scalers. 
 In 1978 Hughes & Caffesse demonstrated that reduction of probing depth 
following mechanical instrumentation results from a combination of gain in 
clinical attachment and increase in gingival recession 
68
. 
 Hill et al. 1981 published a 2-year study of scaling and root planing 
compared to modified Widman surgery. He concluded none of the surgical 
modalities had any better effect than scaling and root planing alone in 
maintenance of periodontal support 
69
. 
 Singletary et al 1982
,
 Greenewell et al 1984 , Lavanchy et al 1987  
reported a significant reduction in gingival inflammation 1-3 months after phase I 
therapy  
70,71,72
. 
 Proye et al 1982  noted recession after one week and a gain of clinical 
attachment by 3 weeks after phase I therapy. After a single episode of scaling and 
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root planing, pockets were reduced to 1.36 mm. This consisted of 0.84 mm 
recession and 0.52 mm attachment gain 
73
. 
 Ramfjord et al 1982 reported that deepest sites demonstrated the greatest 
pocket reduction after instrumentation. They conducted a study in pockets with 1-
3mm, 4-6mm and ≥7mm for 5years and found the greatest pocket reduction in 
group with ≥7mm pocket depth. But they also found a greater amount of 
recession in this group.
74
. 
 IN 1988, Nyman et al showed that it was not necessary to plane the root 
surfaces until smooth or to remove the so called “diseased/ contaminated” 
cementum 
75
.  A clinical study by Oberholzer & Rateitschak 1996
 
concluded that 
the establishment of a smooth and hard root surface was not a critical factor in 
periodontal therapy 
76
. 
 Badersten et al. 1984, Claffey & Egelberg 1995  reported that Non-
surgical periodontal therapy has been proved to be effective in controlling the 
disease in most patients 
77,78
. 
 Philstrom et al. 1984   examined the response of molar and non-molar 
teeth to scaling and root planing alone or scaling and root planing plus a flap 
procedure. At 6 1/2 years, non-molar teeth had an average of about 1.0 mm less 
probing depth than molar teeth irrespective of type of procedure performed and  
no difference in the attachment level for either method  
79
 . 
 Lindhe et al. 1982 determined the critical probing depth for scaling and 
root planing and modified Widman surgery. Probing depths shallower than the 
critical probing depth tend to lose attachment following the procedure. The results 
showed that the critical probing depth for the scaling and root planing group was 
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2.9 mm ± 0.4 and for the modified Widman’s group was 4.2 mm ± 0.2 which 
indicates that in patients with a large number of shallow probing depths, a non-
surgical approach is preferable, while in patients with a large number of pockets > 
4.2 mm, surgical treatment may result in more gain of attachment. The results 
also showed that the level of oral hygiene established during healing and 
maintenance is more critical for the resulting probing depths and attachment 
levels than the mode of treatment used
80.
. 
 Lindhe et al.1984
 
 reported in his 5 year study ,sites with initial probing 
depth exceeding 3 mm responded equally well to non-surgical and surgical 
treatment. The results showed that patients who maintained good oral hygiene 
had more reduction in probing and a greater gain in attachment than patients who 
failed to perform good plaque control, indicating that the patients' self-performed 
plaque control had a decisive influence on the long-term effect of treatment.
81
. 
 Isidor et al. 1984, in a 6-month study on single-rooted teeth, compared 3 
treatments utilizing a split-mouth design: Scaling and root planing versus 
modified Widman surgery versus reverse bevel flap. They concluded that clinical 
gain of attachment was obtained following all 3 modalities but scaling and root 
planing resulted in slightly more gain of attachment than the 2 surgical 
procedures.
82
. 
 Isidor and Karring 1986
 
 reported subgingival scaling at frequent recalls is 
an important factor in halting the progression of disease 
83.
. 
 In general, clinicians should assess healing four to six weeks after 
performing root planning (AAP 1989). Becker and coworkers ( 1990)
 
 noted 
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clinical improvements continued for 8 months, however, most of the healing 
occurred during the first month.
84
. 
 Similarly, Kaldahl and colleagues (1988)
65
 demonstrated that the repair 
process extended for 1 year. It appears that the greatest changes with respect to 
probing depth reduction and gain of clinical attachment can be recorded after 4 to 
6 weeks, but gradual repair and maturation of the periodontium may occur over 9 
to 12 months.
85
  
 Cobb et al  1996 
 
reported that for shallow pockets with initial probing 
depth 1-3mm, the mean reduction of probing pocket depth (PPD) was 0.03mm 
and loss of probing attachment level (PAL) was 0.3mm. For  moderate pockets 
with initial PPD of 4-6mm, the mean reduction of PPD was about 1.29mm and 
the PAL gain was 0.55mm . For deep pockets with initial PPD ≥ 7mm, the mean 
reduction of PPD was about 2.16mm and the PAL gain was 1.19mm .
86 
 
The number of sites that bleed on probing also markedly reduces following 
nonsurgical therapy. Cobb 2002 reviewed many studies and found that the mean 
reduction in bleeding on probing from baseline levels was about 45% 
87
. 
 In  2002 Heitz-Mayfield LJ, Trombelli,et al did a systematic review of the 
effect of surgical debridement vs non-surgical debridement for the treatment of 
chronic periodontitis,the review result was Non surgical periodontal therapy 
(NSPT) has been shown to improve probing pocket depths (PPD) and clinical 
attachment levels (CAL) in mild to moderate periodontitis cases with probing 
pocket  depths of less than 6 mm. In the treatment of deep pockets (> 6 mm) 
surgical periodontal therapy results in greater PPD reduction and clinical 
attachment gain.
88 
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A Systematic review by Tunkel et al 2002  on Machine driven vs 
subgingival debridement ,gave the result that no difference between 
ultrasonic/sonic and manual debridement in the treatment of chronic periodontitis 
89
.Van der Weijden et al 2002 did systematic review on clinical efficacy of  
Subginigvaldebridement with supragingival plaque control, and they concluded 
that  subgingival debridement(with supragingival plaque control improve PPD 
and CAL 
90
 . 
 In 2008,A systematic review by Schwarz et a on l Laser application in 
non-surgical periodontal therapy conclude Er:YAG laser monotherapy resulted in 
similar clinical  outcomes, both in the short and long term compared with 
mechanical debridement. Insufficient evidence to support the clinical application 
of either CO(2), Nd:YAG, Nd:YAP, or different diode lasers 
91 
 
In 2008. Karlsson et al did the systematic review on  The effect of laser 
therapy as an adjunct to non-surgical periodontal  treatment in subjects with 
chronic periodontitis,and conclude that no consistent evidence for efficacy of 
laser as an adjunct to NSPT in adults with chronic periodontitis. 
 In 2009 Slots et al   did the systematic review on The effect of a pulsed 
Nd: YAG laser in non-surgical periodontal therapy. No beneficial effect of a 
pulsed Nd:YAG laser compared to ultrasonics and/or hand instrumentation in the 
initial periodontitis
 92. 
 .
In 2010 Azarpazhooh et al did the systematic review on the effect of 
photodynamic therapy for periodontitis and they concluded that Routine use of 
PDT for clinical management of periodontitis cannot be recommended.   In 2012 
Sgolastra et al did the systematic review on  Efficacy of Er: YAG laser in the 
 REVIEW  OF  LITERATURE 
 
18 
 
treatment of chronic periodontitis and concluded no evidence of effectiveness of 
Er:YAG laser compared to SRP 
93. 
 
 IN 2014 Rahul S Bhansali et al did systematic review of nonsurgical 
therapy by meta analysis and concluded  1,NSPT results in superior clinical 
outcomes as compared to surgical therapy in periodontitis patients with moderate 
pocket depth (≤ 5 mm); (2) Thorough mechanical periodontal therapy (manual 
and ultrasonic debridement) remains a goldstandard resulting in significant 
resolution of periodontal inflammation leading to improvement in the clinical 
signs and symptoms of active disease. But it may be insufficient for complete 
elimination of putative pathogens that may cause reinfection; (3) Adjunctive use 
of lasers or photodynamic therapy in the treatment of periodontitis does not result 
in superior clinical effects compared to that achieved by conventional mechanical 
therapy alone 
95
; 
 In 2014 Anastasios Plessas did a systematic  review on  Nonsurgical 
Periodontal Treatment and he concluded  nonsurgical periodontal treatment 
remains the gold standard for managing the periodontal patients. It can result in 
reduction of inflammation, pocket depth reduction and clinical attachment gain. 
There is no certain magnitude of initial probing pocket depth where nonsurgical 
periodontal therapy is no longer effective
.94. 
 
In 2018 Neshli et al did the study of evaluation of the relationship between 
Cystatin C levels in whole saliva and chronic periodontitis patient ,results showed 
the level of Cystatin C in periodontally diseased subjects was higher than control 
group and concluded the level of Cystatin C in whole saliva could  be used as 
marker 
96 
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                                            MATERIALS AND METHODS 
Study population: 
The study population was selected from the out patient section of the 
Department of Periodontics, Tamil Nadu Government Dental College and Hospital, 
Chennai . 
Sample procedure: 
The type of sampling  was  convenience  sampling. 
Sample size: 30 
Subjects  divided into three groups : 
Test group : 
Group I- 10 subjects with chronic periodontitis (study group) –  30 -45 years 
of age  having probing depth ≥ 5mm and /or clinical attachment level (CAL )> 30% 
sites with varying degree of disease severity. 
Group II- 10 subjects with aggressive periodontitis (study group)-< 30 years of 
age having probing depth of ≥ 5 mm and /or CAL on 8 or more teeth ,at least three of  
which  were  not first molars and incisors  with varying degree of  disease severity. 
Control group : 
Group III-10  subjects with healthy periodontium. – probing depth -2-3  mm  
Eligibility criteria: 
Inclusion criteria - 
 Periodontally healthy individuals - For control group 
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 Either sex. 
 Study group: Patients affected with chronic periodontitis showing probing 
pocket depths > 5mm.  
 Patients with  untreated  aggressive  periodontitis 
 Agreement to participate in study program. 
Exclusion criteria - 
 Smokers and tobacco users 
 Patients with systemic diseases 
 Medically compromised patients such as uncontrolled diabetes, 
immunosuppression, bleeding disorders, cancer, stroke and severe 
osteoporosis. 
 Patient who underwent periodontal treatment in past 6 months.  
 Patient under drugs which affects serum cystatin c levels. 
 Pregnancy and lactation 
 Patients under bisphosphonates medication 
 Patients who had received any antibiotic therapy in the last 6 months. 
STUDY DESIGN  
The study was carried out in 30 subjects divided into 3 groups with 10 subjects 
in each group: Group I- Generalized Chronic Periodontitis, Group II-Generalized 
Aggressive Periodontitis and Group III- Healthy periodontium (Control Group). 
Ethical clearances were obtained from the Institutional Ethical Committee and ethical 
principles were meticulously followed throughout the study. After explaining the 
study protocol (Annexure 1&3), informed consent was obtained from all the selected 
subjects (Annexure 2 & 4). A thorough medical and dental history of the subjects was 
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taken. All the subjects underwent full-mouth periodontal probing and charting and 
clinical and laboratory evaluation (Annexure 5).  
METHOD OF COLLECTING DATA 
ARMAMENTATIUM 
 For clinical examination 
1.Mouth mirror 
2.William’s Probe 
3.Curved Explorer 
4.Dental tweezers 
5.Cotton rolls 
6.Sterilized disposable gloves 
7. Disposable face masks and head cap 
8. Kidney tray 
 For collection of blood sample 
1. Sterile cotton 
2. Surgical spirit 
3. Disposable syringe with 22gauge needle 
4. Tourniquet. 
For Phase I therapy 
1. Mouth mirror 
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2. Explorer 
3. Scalers and curette 
4. Kidney Tray  
5. Cotton Rolls 
6. Disposable Gloves 
7. Disposable Facemask 
8. Disposable Head cap 
9. Disposable syringe 24 gauge needle 
10. Local Anaesthetic solution 
12.0.9 % Normal saline 
13. Ultrasonic scaling unit  
CLINICAL PARAMETERS ASSESSMENT  
The following clinical parameters were evaluated for all the subjects:  
1. Plaque index – Silness and Loe 1964 
2. Gingival bleeding index – Ainamo and Bay 1975  
3. Probing depth in mm (PD)  
4. Clinical attachment level in mm (CAL)  
Plaque Index (Silness and Loe 1964)  
All teeth were examined at 4 sites each (disto-facial, facial, mesio-facial, lingual / 
palatal) and were scored as follows:  
Scoring Criteria:  
Score 0: No plaque in the gingival area.  
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Score 1: A film of plaque adhering to the free gingival margin and adjacent area of 
the tooth. The plaque is recognized only by running a probe across the tooth surface.  
Score 2: Moderate accumulation of plaque within the gingival pocket and on the 
gingival margin and / or adjacent tooth surface that can be seen by the naked eye.  
Score 3: Abundance of soft deposits within the gingival pocket and / or on the 
gingival margin and adjacent tooth surface.  
Calculation:  
Plaque index per tooth = Total score/4  
Plaque index per individual ═ Total P I per tooth / Total number of teeth examined  
Interpretation:  
Score 0 – Excellent oral hygiene  
0.1 to 0.9 – Good oral hygiene 
1.0 to 1.9 – Fair oral hygiene 
2.0 to 3.0 - Poor oral  
Gingival Bleeding Index (Ainamo& Bay 1975)  
Starting distobuccally, the probe was gently inserted into the sulcus and run to 
the buccal and mesial surfaces of every tooth at an angle of about 45º. This was 
repeated for all the teeth present. Similarly probing was carried out at palatal/lingual 
sites. The total number of bleeding sites per tooth was thus recorded for every tooth 
except the third molar.  
Scoring Criteria:  
Positive score (1) - Presence of bleeding within 10 seconds  
Negative score (0) - Absence of bleeding  
% of bleeding sites = Total number of positive score x 100  
                                   Total number of surfaces of all teeth  
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Probing Pocket Depth (PPD)  
Probing Pocket Depths were measured from the gingival margin to the base of 
the pocket in millimeters using William’s Periodontal Probe. The probe was walked 
within the gingival sulcus along the circumference of the tooth. Keeping the probe 
parallel to the long axis of the selected tooth, six measurements were made per tooth 
(Mesiobuccal, Distobuccal, Midbuccal, Mesiolingual, Distolingual and Midlingual).  
Clinical Attachment Level (CAL)  
Clinical Attachment Level was measured from the Cemento – Enamel Junction 
(CEJ) to the base of the pocket using William‘s Periodontal Probe.  
When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing depth, the distance from 
the gingival margin to the CEJ. If both were the same, the loss of attachment was 
calculated to be zero.  
When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equaling the probing depth.  
When the gingival margin was located apical to the CEJ, the loss of attachment 
was greater than the probing depth and therefore the distance between the CEJ and the 
gingival margin were added to the PD.  
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth ( Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual, Midlingual, and Distolingual).  
Radiographic parameters: 
 Radiographs were taken to assess the bone loss. 
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Routine blood investigation was done 
 Haemoglobin% 
 Bleeding time 
 Clotting time 
 Total leukocyte count 
 Differential leukocyte count 
 Random sugar 
ESTIMATION OF SERUM CYSTATIN C LEVEL; 
METHOD OF COLLECTION OF BLOOD SAMPLE  
Venous blood was drawn from the participants selected for the study. The subjects 
were informed, and consent was taken. They were made to tighten a fist so that vein 
was more palpable, and antecubital vein was selected for venipuncture. A tourniquet 
was applied about 1-2 inches above the antecubital fossa. After disinfecting  the 
puncture site with 10%  isopropanol solution, blood was withdrawn using a syringe 
with 22  gauge needle. Tourniquet was released as the blood flow began. After 
drawing 3 mL of blood, sterile cotton ball was placed on the puncture site and needle 
was withdrawn. The subjects were instructed to apply mild finger pressure on the site 
for few minutes to avoid oozing out of blood.  
The blood sample was allowed to clot atroom temperature and, after 1 h, 
serum was separated from blood by centrifuging at 3000g for 5 min. The extracted 
serum was immediately transferred to a plastic vial and stored at −70◦C till the time of 
assay.Quantitative determination of cystatinc  in patient's serum was done by enzyme-
linked immunosorbent assay (ELISA) method.  
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PRINCIPLE OFASSAY; 
Qualitative determination of c reactive protein in patient blood was done by 
double antibody sandwich ELISA method. In this assay, the Cystatin C present in 
sample reacts with anti humancystatin c antibodies which was  precoated  in microtitre 
wells. After the removal of unbound sample proteins by washing, polyclonal antibody 
aginstCSTC  conjugated with horseradish peroxidase proteins were added. These 
enzyme labeled antibodies formed complexes with the previously bound CystatinC. 
Following another washing step, the enzyme bound to the immunosorbent is assayed 
by the addition of a chromogenic substrate 0,3’-8’5 -tetramethylbenzidine(TMB). The 
quantity of bound enzyme varies directly with concentration of Cystatin C in the test 
sample.  The quantity of CystatinC  in test sample can be interpolated from the 
standard curve constructed from standard and corrected for serum dilution. 
Reagents used; 
1.Anti-Human Cystatin C Precoated 96-well Strip Plate 1 each 
2.Lyophilized Recombinant Human Cystatin C Standard 2 vials 
3.20X Wash Buffer 25mL 
4.Biotinylated Antibody Reagent 2 vials 
5.Streptavidin-HRP Reagent 200Ul 
6.TMB Substrate 12mL 
7.Stop Solution, contains 0.2M sulfuric acid 8mL 
8.Assay Diluent, 5X concentrated buffer 15Ml. 
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                                         CSTC DETERMINATION  
 
                                             Method- Sandwich  Elisa 
 
                                     Patient  blood sample was collected. 
 
                                             Serum separated   
 
                                           Sample added to microtitre wells.  
 
      CSTC present in serum  sample bound with Ab which was precoatedin                                                                                                                                                      
microtiter wells .  
                        Microtitre wells washed to remove unbound proteins.  
 
         Anti-polyclonal CSTC  Abs conjugated with horseradish peroxidase added.  
 
                              These enzymes complex with bound CSTC 
 
                                 Again washed to remove unbound enzyme. 
 
                                   Chromogenic substrate 0,3’-8’5 added.  
 
        Enzyme bound to chromogenic substrate is assessed quantitatively.  
 
                Quantity of bound enzyme is proportional to conc. of CSTC  
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Procedure; 
1. all reagents and samples were brought to room temperature (18 - 25ºC) before 
use.  
2. Standard no.7 (20ng/ml) in duplicate  
Standard no.6 (10ng/ml) in duplicate 
Standard no.5 (5ng/ml) in duplicate  
Standard no.4 (2.5ng/ml) in duplicate 
Standard no.3 (1.25ng/ml) in duplicate 
Standard no.2 (0.625ng/ml) in duplicate 
Standard no.1 (0.313ng/ml) in duplicate , were pipette out. 
3. 100μL of each standard  and sample were added  into appropriate wells. 
4.  Wells were coverd and incubatefor 2.5 hours at room temperature with gentle 
shaking. 
5. The solution  was discarded and washed  4 times with WashBuffer.solution .  
6. Plate  was inverted and bloted it against clean papertowels. 
7.   100μL of  prepared biotinylated  antibody were added   to each well and 
incubated for 1 hour at roomtemperature with gentle shaking. 
8.  The solution.was discarded and washed with wash buffer solution . 
9. 100μL of prepared Streptavidin-HRP solution were added  to each well and  
Incubated for 45 minutesat room temperature with gentle shaking.. Discard the 
solution and washed . 
10.  100μL of TMB Substrate were added  to each well and Incubated for 30 
minutes at room temperature in the dark with gentle shaking 
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11. Stop solution was added . The plate was evaluated within 30 minutes of 
stopping the reaction. Measure absorbance on an ELISA plate reader setat 
450nmwave length.. 
12. Optical density (OD) of standard, control and samples were read at 450nm. 
Difference of OD was calculated, thereby plotting a standard curve and 
concentration of control, standard and sampled were read and corrected for 
sera dilution . 
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                             PHOTOGRAPH 1: GROUP I-GENERALISED CHRONIC PERIODONTITIS (BASELINE) 
 
 
 
 
                    PHOTOGRAPH 2: GROUP I-GENERALISED CHRONIC PERIODONTITIS (3 MONTHS POST OP)   
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   PHOTOGRAPH 3-GROUP II GENERALISED AGGRESSIVE  PERIODONTITIS  BASELINE 
 
                                  
  PHOTOGRAPH 4: GROUP II  GENERALISED AGGRESSIVE  PERIODONTITIS (3 MONTHS 
POST OP) 
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         PHOTOGRAPH 5: GROUP III-CONTROL GROUP 
 
 
 
I  
   
 PHOTOGRAPH 6 : ARMAMENTAR UM FOR BLOOD COLLECTION 
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PHOTOGRAPH 7 : COLLECTION OF VENOUS BLOOD SAMPLE 
 
         PHOTOGRAPH 8 : ARMAMENTARIUM FOR PHASE I THERAPY 
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   PHOTOGRAPH 10: ARMAMENTARIUM FOR SAMPLE TRANSPORTATION 
 
 
 
 
                                             PHOTOGRAPH 11: ELISA READER 
                                                                                         STATISTICAL ANALYSIS                                                                                    
 
35 
 
                                            STATISTICAL ANALYSIS  
The statistical analysis was done using the computer software program SPSS 
version 20; (Statistical Package for Social Science, Version 20;Chicago IL,USA). 
Data was expressed as mean ± standard deviation of the parameters evaluated. In all 
the groups, the clinical and laboratory parameters were evaluated at baseline and 3 
months post operatively.  
STATISTICAL TESTS USED:  
1.TESTS OF NORMALITY: SHAPIRO WILK’S TEST –  
2. INTERGROUP COMPARISON – ONE WAY ANOVA  
To compare the parameters between  groupI.,groupII,and group III ,ONE 
WAY ANOVA  were used 
3. INTERGROUP COMPARISON -UN PAIRED T TEST 
Tocompare the parameters between group I and group II , UN PAIRED T 
TEST were  used  
4. INTRAGROUP COMPARISON – PAIRED SAMPLE T TEST  
              P value of <0.05 is considered significant in the present study.  
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             In the present interventional study, 30 subjects were included, among them 
10 subjects with Generalized Chronic Periodontitis were categorized as Group I , 10 
subjects with Generalized Aggressive Periodontitis were categorized as Group II and 
10 non-periodontitis patients(Control) were categorized as Group III. There were 5 
males and 5 females in each group, with a mean age of 41.4 ±4.16  years in Group I, 
27.3 ±3.43S in Group II and  29.3± 2.83 years in Group III. The parameters assessed 
were plaque index, gingival bleeding index, probing depth and clinical attachment 
level (clinical) and serum Cystatin  C  level (laboratory) at  baseline and 3 months 
post-operatively 
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1. PLAQUE INDEX  
Intragroup comparison  
Group I: The mean plaque index score at baseline was 2.49± o.28 and at 3 months 
was  
0.86±032. The mean difference in plaque score from baseline to 3 month was 
statistically significant (p=0.000).  
Group II: The mean plaque index score at baseline was 2.25 ± 0.15 and at 3 months 
was  
0.72± 0.13. The mean reduction in plaque score from baseline to 3 months was 
statistically significant (p=0.000).  
Group III: The mean plaque index score at baseline was 0.57 ± 0.13   
(Table no. 7) & (Figure no. 1)  
 
 
Intergroup comparison  
Mean difference between group I and group II at baseline was 0.23800 which was 
statistically significant (p=0.036) and at 3 months post-op was 0.14 which was 
statistically significant (p=0.027).  
Mean difference between group I and group III at baseline was 1.919 which was 
statistically significant (p=0.000)  
Mean difference between group II and group III at baseline was 1.681 which was 
statistically significant (p=0.000)  
Table no. 12  
                                                                                                                                      RESULTS 
 
38 
 
PROBING POCKET DEPTH  
Intragroup comparison  
Group I: The mean PPD at baseline was 5.74±0.89 and at 3 months was 3.48±0.87. 
The mean reduction in PPD from baseline to 3 months was statistically significant 
(p=0.000).  
Group II: The mean PPD at baseline was 4.011±0.57 and at 3 months was 
2.630±0.40. The mean reduction in PPD from baseline to 3 months was statistically 
significant (p=0.000).  
Group III: The mean PPD at baseline was 2.15±0.14  
Intergroup comparison  
Mean difference between group I and group II at baseline was 1.727 which was 
statistically-significant (p=0.000) and at 3 months post-op was 0.85 which was 
statistically non-significant (p=0.106).  
Mean difference between group I and group III at baseline was 3.588 which was 
statistically significant (p=0.000) .Mean difference between group II and group III at 
baseline was 1.861 which was statistically significant (p=0.000)  
(Table 8;figure 2) 
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CLINICAL ATTACHMENT LEVEL  
Intragroup comparison  
Group I: The mean CAL at baseline was 5.57 ±0.92 and at 3 months was 3.62±0.88. 
The mean reduction in CAL from baseline to 3 months was statistically significant 
(p=0.000).  
Group II: The mean CAL at baseline was 4.120±0.56 and at 3 months was 
2.672±0.41. The mean reduction in CAL from baseline to 3 months was statistically 
significant (p=0.000).  
Group III: There was no CAL either at baseline or 3 months post-op.  
(Table no. 9) & (Figure no. 3)  
Intergroup comparison  
Mean difference between group I and group II at baseline was 1.45 which was 
statistically non-significant (p=0.000) and at 3 months post-op was 0.95 which was 
statistically significant (p=0.003).  
(Table no;15)& (Figure no. 3) 
GINGIVAL BLEEDING INDEX 
Intragroup comparison  
Group I: The mean GBI at baseline was 77.91 ± 11.3 and at 3 months was 14.69±6.4. 
The mean reduction in GBI from baseline to 3 months was statistically significant 
(p=0.000).  
Group II: The mean GBI at baseline was 84.640±7.61 and at 3 months was 
15.900±4.2 The mean reduction in GBI from baseline to 3 months was statistically 
significant (p=0.000).  
Group III: There was no GBI . 
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Intergroup comparison  
Mean difference between group I and group II at baseline was -6.73  which was 
statistically significant (p=0.000) and at 3 months post-op was -1.21 which was 
statistically non-significant (p=0.316).  
(Table no;10)& (Figure no. 4) 
 
SERUM CYSTATIN C  
Intragroup comparison  
Group I: The mean serum Cystatin C at baseline was 995.5±68.17 and at 3 months 
was 897.2±56.19. The mean reduction in serum Cystatin C from baseline to 3 months 
was statistically significant (p=0.000).  
Group II: The mean serum Cystatin C at baseline was 1198.94±31.51 and at 3 
months was 939.92±44.68. The mean reduction in serum Cystatin C  from baseline to 
3 months was statistically significant (p=0.000).  
Group III: The mean serum Cystatin C at baseline was 737.6± 24.6 . 
Intergroup comparison  
Mean difference between group I and group II at baseline was -203.380 which was 
statistically significant (p=0.000) and at 3 months post-op was -42.7 which was 
statistically significant (p=0.002).  
Mean difference between group I and group III at baseline was 257.97 which was 
statistically significant (p=0.000) . 
Mean difference between group II and group III at baseline was 461.35 which was 
statistically significant (p=0.000). 
(Table no;11)& (Figure no. 5) 
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TABLE 1: MASTER CHART- GROUP 1 (CLINICAL PARAMETERS) 
 
GROUP I CHRONIC PERIODONTITIS (CLINICAL PARAMETERS) 
S.N
O 
AGE SEX 
BASELI
NE             
PI 
BASE
LINE  
PPD 
BASEL
INE 
CAL 
BASELI
NE GBI 
3 
MONT
HS PI 
3 
MONT
HS PPD 
3 
MONT
HS  
CAL 
3 
MONT
HS GBI 
1 40 F 2.38 5.81 5.1  83.7 0.87 3.32 3.65 13.4 
2 45 F 2.13 4.18 4.07 68.4 0.62 2.14 2.5 10.5 
3 45 F 2.76 6.26 6.18 79.4 0.98 4.21 4.33 22.6 
4 45 F 2.67 6.12 6.14 80.5 0.42 4.02 4.22 17.6 
5 45 M 2.56 7.12 6.98 91.5 1.05 5.02 5.22 28.6 
6 38 F 2.45 6.38 6.24 67.5 1.21 4.02 4.12 11.2 
7 40 M 2.78 6.28 6.22 87.6 0.76 3.48 3.5 14.4 
8 32 M 1.98 5.13 5.08 55.6 0.32 3.03 3.13 9.5 
9 42 M 2.8 5.5 5.25 89.5 1.05 3.28 3.22 10.5 
10 42 M 2.34 4.6 4.4 75.4 1.32 2.3 2.33 8.6 
 
 
 
                                                                                                                                     RESULTS 
 
42 
 
TABLE 2: MASTER CHART- GROUP II (CLINICAL PARAMETERS) 
 
GROUP II  AGGRESSIVE PERIODONTITIS (CLINICAL PARAMETERS) 
 
S.N
O 
AG
E 
 
SE
X 
BASELI
NE  PI 
BASELI
NE PPD 
BASELI
NE 
CAL 
BASELI
NE GBI 
3 
MONT
HS PI 
3 
MONT
HS 
PPD 
3 
MONT
HS 
CAL 
3 
MONT
HS 
GBI 
1 29  M 2.34 3.8 3.9 85.7 0.86 2.49 2.5 20.2 
2 30  F 2.46 4.4 4.3 75.4 0.82 2.95 3.01 15.2 
3 29  M 2.32 4.5 4.5 88.4 0.75 2.25 2.35 18.2 
4 20  F 1.98 2.91 3.01 90.5 0.5 2.39 2.48 25.2 
5 29  M 2.16 3.26 3.48 87.6 0.78 2.12 2.12 17.2 
6 30  F 2.24 3.57 3.61 91.6 0.95 2.05 2.08 11.5 
7 24  F 2.14 4.63 4.5 65.7 0.54 3.29 3.35 10.5 
8 28  M 2.41 4.02 4.92 89.5 0.72 3.03 3.13 14.8 
9 24  M 2.04 4.5 4.5 85.2 0.67 2.98 2.95 12.5 
10 30  F 2.38 4.52 4.48 86.8 0.56 2.75 2.75 13.7 
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 TABLE 3: MASTER CHART - GROUP III (CLINICAL PARAMETERS) 
GROUP III CONTROL GROUP (CLINICAL PARAMETERS) 
S.NO AGE SEX 
BASELIN
E PI 
BASELIN
E PPD 
BASELIN
E CAL 
BASELIN
E GBI 
1 32 F 0.65 2.38 0 0 
2 29 M 0.45 2.4 0 0 
3 35 M 0.85 2.02 0 0 
4 25 F 0.56 2 0 0 
5 29 M 0.64 2.16 0 0 
6 30 F 0.5 2.18 0 0 
7 30 M 0.45 2.13 0 0 
8 25 F 0.48 1.98 0 0 
9 30 M 0.43 2.19 0 0 
10 28 F 0.65 2.06 0 0 
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TABLE 4: MASTER CHART - GROUP I (LABORATORY PARAMETER) 
GROUP I CHRONIC PERIODONTITIS ( 
LABORATORY VALUES) ng/ml 
S.NO AGE  SEX BASELINE  
CYSTATIN C  
3 MONTHS 
CYSTATIN C  
1 40 F 1015.8 887.3 
2 45 F 956.7 832.1 
3 45 F 1120.1 897.2 
4 45 F 986.2 798.4 
5 45 M 1012.3 858.3 
6 38 F 997.2 835.4 
7 40 M 1056.3 825.2 
8 32 M 855.3 726.9 
9 42 M 982.5 822.1 
10 42 M 973.2 736.4 
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TABLE 5: MASTER CHART- GROUP II (LABORATORY PARAMETER) 
GROUP II AGGRESSIVE PERIODONTITIS ( 
LABORATORY PARAMETERS)ng/ml 
S.NO AGE SEX 
BASELINE 
CYSTATIN 
C 
3 MONTHS 
CYSTATIN C 
1 29 M 1162.2 956.1 
2 30 F 1235.2 986.3 
3 29 M 1252.6 867.8 
4 20 F 1173.5 986.2 
5 29 M 1168.3 988.5 
6 30 F 1182.3 929 
7 24 F 1174.5 892.5 
8 28 M 1203.1 872.4 
9 24 M 1195.2 967.3 
10 30 F 1242.5 953.1 
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TABLE 6: MASTER CHART- GROUP III (LABORATORY PARAMETERS) 
 
 
 
 
GROUP III (LABORATORYPARAMETERS )ng/ml 
S.NO AGE SEX CYSTATIN  C 
VALUE 
1 32 F 731.6 
2 29 M 745.2 
3 35 M 756 
4 25 F 721.2 
5 29 M 705.6 
6 30 F 770.2 
7 30 M 759.1 
8 25 F 712.2 
9 30 M 765.3 
10 28 F 709.5 
                                                                                                                                     RESULTS 
 
47 
 
 
 
TABLE 7: COMPARISON OF PLAQUE SCORES 
 
GROUPS 
BASELINE PI 
(MEAN ± SD) 
3 MONTHS PI 
(MEAN ± SD) 
P VALUE 
GROUP 1 2.49  ± .28 .86 ± .32 .000* 
GROUP 2 2.25 ± .15 .72 ± .13 .000* 
GROUP 3 .57 ± .13   
P VALUE .000** .027***  
 
*PAIRED T TEST, **ONE WAY ANOVA, ***UNPAIRED T TEST 
                      TABLE 8: COMPARISON OF PROBING POCKET DEPTH 
 
GROUPS 
BASELINE PPD 
(MEAN ± SD) 
3 MONTHS PPD 
(MEAN ± SD) 
P VALUE 
GROUP 1 5.47 ± .89 3.48 ± .87 .000* 
GROUP 2 4.01 ± .57 2.63 ± .40 .000* 
GROUP 3 2.15 ± .14   
P VALUE .000** .106***  
 
*PAIRED T TEST, **ONE WAY ANOVA, ***UNPAIRED T TEST 
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                  TABLE 9: COMPARISON OF CLINICAL ATTACHMENT LOSS  
 
GROUPS 
BASELINE CAL 
(MEAN ± SD) 
3 MONTHS CAL 
(MEAN ± SD) 
P VALUE 
GROUP 1 5.57 ± .92 3.62 ± .88 .000* 
GROUP 2 4.12 ± .56 2.67 ± .41 .000* 
GROUP 3 0   
P VALUE .000** .003***  
 
*PAIRED T TEST, **ONE WAY ANOVA, ***UNPAIRED T TEST 
 
TABLE 10: COMPARISON OF GINGIVAL BLEEDING INDEX  
 
GROUPS 
BASELINE GBI 
(MEAN ± SD) 
3 MONTHS GBI 
(MEAN ± SD) 
P VALUE 
GROUP 1 77.91 ± 11.3 14.69 ± 6.4 .000* 
GROUP 2 84.64 ± 7.61 15.9 ± 4.2 .000* 
GROUP 3 0   
P VALUE .000** 0.316***  
 
*PAIRED T TEST, **ONE WAY ANOVA, ***UNPAIRED T TEST 
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TABLE 11: COMPARISON OF SERUM  OF CYSTATIN C LEVEL 
 
GROUPS 
BASELINE CYSTATIN 
C 
(MEAN ± SD) 
3 MONTHS CYSTATIN 
C 
(MEAN ± SD) 
P VALUE 
GROUP 1 995.56 ± 68.17 897.2 ± 56.19 .000* 
GROUP 2 1198.9 ± 31.51 939.9 ± 44.68 .000* 
GROUP 3 737.6 ± 24.6   
P VALUE .000** .002***  
 
*PAIRED T TEST, **ONE WAY ANOVA, ***UNPAIRED T TEST 
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TABLE 12: TUKEY POST HOC ANALYSIS FOR BASELINE PI VALUES 
BETWEEN 3 GROUPS 
 
DEPENDENT 
VARIABLE 
(I) 
GROUPS 
(J) 
GROUPS 
MEAN 
DIFFERENCE 
STD. 
ERROR 
SIG 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE 
PI 
GROUP 
1 
GROUP 
2 .23800 .09069 .036 .0131 .4629 
GROUP 
3 1.91900 .09069 .000 1.6941 2.1439 
GROUP 
2 
GROUP 
1 -.23800 .09069 .036 -.4629 -.0131 
GROUP 
3 1.68100 .09069 .000 1.4561 1.9059 
GROUP 
3 
GRUOP 
1 -1.91900 .09069 .000 
-
2.1439 
-
1.6941 
GROUP 
2 -1.68100 .09069 .000 1.9059 1.4561 
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TABLE 13 :TUKEY POST HOC ANALYSIS FOR BASELINE PPD VALUES 
BETWEEN 3 GROUPS 
 
DEPENDENT 
VARIABLE 
(I) 
GROUPS 
(J) 
GROUPS 
MEAN 
DIFFERENCE 
STD. 
ERROR 
SIG 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
 
BASELINE 
PPD 
GROUP 
1 
GROUP 
2 1.72700 .28114 .000 1.0299 2.4241 
GROUP 
3 3.58800 .28114 .000 2.8909 4.2851 
GROUP 
2 
GROUP 
1 -1.72700 .28114 .000 
-
2.4241 
-
1.0299 
GROUP 
3 1.86100 .28114 .000 1.1639 2.5581 
GROUP 
3 
GRUOP 
1 -3.58800 .28114 .000 
-
4.2851 
-
2.8909 
GROUP 
2 -1.86100 .28114 .000 
-
2.5581 
-
1.1639 
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TABLE 14 :TUKEY POST HOC ANALYSIS FOR BASELINE CYSTATIN C 
VALUES BETWEEN 3 GROUPS 
 
DEPENDENT 
VARIABLE 
(I) 
GROUPS 
(J) 
GROUP
S 
MEAN 
DIFFERENCE 
STD. ERROR SIG 
95% CONFIDENCE 
INERVAL 
LOWER UPPER 
 
 
BASELINE 
CYSTATIN 
C 
GROUP 
1 
GROUP 
2 
-
203.3800
0 
20.5874
1 
.00
0 
-
254.424
8 
-
152.335
2 
GROUP 
3 
257.9700
0 
20.5874
1 
.00
0 
206.925
2 
309.014
8 
GROUP 
2 
GROUP 
1 
203.3800
0 
20.5874
1 
.00
0 
152.335
2 
254.424
8 
GROUP 
3 
461.3500
0 
20.5874
1 
.00
0 
410.305
2 
512.394
8 
GROUP 
3 
GRUOP 
1 
-
257.9700
0 
20.5874
1 
.00
0 
-
309.014
8 
-
206.925
2 
GROUP 
2 
-
461.3500
0 
20.5874
1 
.00
0 
-
512.394
8 
-
410.305
2 
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TABLE 15 :UNPAIRED T TEST  FOR INTERGROUP COMPARISION 
BETWEEN GROUP 1 AND II 
Independent Samples Test 
  Levene'
s Test 
for 
Equalit
y of 
Varianc
es 
t-test for Equality of Means 
  F Si
g. 
t df Sig. 
(2-
tail
ed) 
Mean 
Differ
ence 
Std. 
Error 
Differ
ence 
95% Confidence 
Interval of the 
Difference 
  Lowe
r 
Upper 
AGE Equal 
variances 
assumed 
.11
8 
.7
35 
8.2
56 
18 .00
0 
14.10
000 
1.707
83 
10.51
199 
17.68801 
Equal 
variances 
not 
assumed 
  8.2
56 
17.
362 
.00
0 
14.10
000 
1.707
83 
10.50
253 
17.69747 
BASELINE
PI 
Equal 
variances 
assumed 
3.2
30 
.0
89 
2.3
13 
18 .03
3 
.2380
0 
.1028
9 
.0218
3 
.45417 
Equal 
variances 
not 
assumed 
  2.3
13 
14.
366 
.03
6 
.2380
0 
.1028
9 
.0178
4 
.45816 
BASELINE
PPD 
Equal 
variances 
assumed 
1.3
15 
.2
66 
5.0
62 
18 .00
0 
1.727
00 
.3411
6 
1.010
24 
2.44376 
Equal 
variances 
not 
assumed 
  5.0
62 
15.
808 
.00
0 
1.727
00 
.3411
6 
1.003
05 
2.45095 
BASELINE
CAL 
Equal 
variances 
assumed 
3.3
11 
.0
85 
4.1
50 
18 .00
1 
1.446
00 
.3483
9 
.7140
5 
2.17795 
Equal   4.1 15. .00 1.446 .3483 .7048 2.18717 
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variances 
not 
assumed 
50 336 1 00 9 3 
BASELINE
GBI 
Equal 
variances 
assumed 
1.5
94 
.2
23 
-
1.5
32 
18 .14
3 
-
6.730
00 
4.394
08 
-
15.96
162 
2.50162 
Equal 
variances 
not 
assumed 
  -
1.5
32 
16.
203 
.14
5 
-
6.730
00 
4.394
08 
-
16.03
555 
2.57555 
THREEMO
NTHSPI 
Equal 
variances 
assumed 
5.7
60 
.0
27 
1.2
72 
18 .22
0 
.1450
0 
.1139
8 
-
.0944
7 
.38447 
Equal 
variances 
not 
assumed 
  1.2
72 
12.
477 
.22
7 
.1450
0 
.1139
8 
-
.1022
9 
.39229 
THREEMO
NTHSPPD 
Equal 
variances 
assumed 
2.9
03 
.1
06 
2.7
57 
18 .01
3 
.8520
0 
.3090
6 
.2026
8 
1.50132 
Equal 
variances 
not 
assumed 
  2.7
57 
13.
055 
.01
6 
.8520
0 
.3090
6 
.1846
0 
1.51940 
THREEMO
NTHSCAL 
Equal 
variances 
assumed 
3.4
71 
.0
79 
3.0
55 
18 .00
7 
.9500
0 
.3109
2 
.2967
8 
1.60322 
Equal 
variances 
not 
assumed 
  3.0
55 
13.
107 
.00
9 
.9500
0 
.3109
2 
.2788
6 
1.62114 
THREEMO
NTHSGBI 
Equal 
variances 
assumed 
1.0
57 
.3
18 
-
.48
7 
18 .63
2 
-
1.210
00 
2.485
89 
-
6.432
66 
4.01266 
Equal 
variances 
not 
assumed 
  -
.48
7 
15.
957 
.63
3 
-
1.210
00 
2.485
89 
-
6.481
01 
4.06101 
BaselineC
ystatinC 
Equal 
variances 
assumed 
1.1
10 
.3
06 
-
8.4
80 
18 .00
0 
-
203.3
8000 
23.98
292 
-
253.7
6624 
-
152.99376 
Equal   - 13. .00 - 23.98 - -
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variances 
not 
assumed 
8.4
80 
046 0 203.3
8000 
292 255.1
7343 
151.58657 
Threemont
hsCystatin
C 
Equal 
variances 
assumed 
.00
8 
.9
28 
-
5.0
87 
18 .00
0 
-
117.9
9000 
23.19
559 
-
166.7
2213 
-69.25787 
Equal 
variances 
not 
assumed 
  -
5.0
87 
17.
463 
.00
0 
-
117.9
9000 
23.19
559 
-
166.8
2975 
-69.15025 
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Figure 1: Comparison of Plaque Index between Group I, Group II and Group III 
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Figure 2: Comparison of Probing Pocket Depth between Group I, Group II and Group III 
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Figure 3: Comparison of Clinical attachment level (CAL) between Group I, 
Group II  
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Figure 4: Comparison of Gingival Bleeding Index between Group I, Group II  
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Figure 5: Comparison of serum Cystatin  C between Group I, Group II and 
Group III 
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                                                   DISCUSSION  
                         Periodontitis is an inflammatory disease of the supporting tissues 
surrounding the teeth caused by gram negative anaerobic   microorganisms, resulting 
in progressive destruction of the periodontal ligament which is left untreated will 
progress to alveolar bone destruction ultimately resulting in tooth loss.  Periodontitis 
is broadly classified into two groups; chronic periodontitis and aggressive 
periodontitis. Both forms represent the same  patho physiology  with varying nature of 
disease severity and rate of progression. 
                         In the present study, 30 subjects were selected, among them 10 
subjects with Generalized Chronic Periodontitis were categorized as Group I , 10 
subjects with Generalized Aggressive Periodontitis were categorized as Group II and 
10 healthy subjects (Control) were categorized as Group III.  
                        Several studies(Henskens et al  1996,Baron et al 1999, lie et al 
2001,Gils et al 2003. Ulker et al   2008, Graziani et al 2010,) 
16,57,59,61,64,66 
have been 
carried out to evaluate Cystatin C level in saliva, serum and GCF in patients of 
gingivitis and  chronic periodontitis. Ulker et al reported decreased levels of CSTC  
in gingival crevicular fluid (GCF) and total saliva in children with gingivitis 
compared to periodontally healthy childrens 
64
. While Henskens et al. found no 
CSTC levels in GCF samples while increased concentrations of  CSTC  were detected 
in whole saliva in both gingivitis and periodontitis subjects in comparison with 
healthy subjects. Considering the above studies, the levels of CSTC in GCF and saliva 
in periodontal diseases are controversial 
16
.  
                          Anuj Sharma et al  2012 study  compared the serum Cystatin C level  
and GCF Cystatin C in  healthy  ,gingivitis and  chronic periodontitis and  reported   
increased  Cystatin C level in both GCF and serum  in periodontitis group than 
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healthy 
5
 . But  none of the study compared the serum Cystatin C level in both chronic 
and aggressive periodontitis to find out  difference in both form of periodontitis..  
                     In the present study, subjects with  acute or chronic systemic conditions 
,inflammatory conditions like rheumatoid arthritis, cardiovascular disease etc. have 
been excluded because these conditions can cause increased Cystatin C level on their 
own (Leung – Tack et al 1990,Strojan 2004.,Levy 2001,Bokarewa M et al 2007 ), 
which may lead to confounding effect in the study .
43,45,47,48
      . 
                       Patients under medications like antibiotics, corticosteroids, anti-
inflammatory drugs for past 3 months and those underwent periodontal therapy within 
past six months  (Foster et al  2006)
9
  have been excluded because these therapies can 
suppress the inflammatory process and may lead to confounding effect in the study.  
                     In the present study the influence of age and gender of the subjects on 
the CSTC concentration was minimised/nullified by including the equal number of 
,males and female in each group and selecting the subjects within the specified age 
group of 20–50 years. 
                    Quantitative determination of Cystatin C in the present study in all the 
groups was done by double antibody sandwich ELISA method which is very sensitive 
method for detecting Cystatin C as compared to other methods. 
                     In the present study, clinical parameters like plaque index, PPD, CAL, 
gingival bleeding index were also assessed and compared among the three groups to 
correlate with the levels of serum Cystatin C to establish a relationship between 
Cystatin C levels and periodontal disease status.    Plaque Index, PPD, CAL values at 
baseline in group I (2.49± 0.28, 5.47±0.89, 5.57 ±0.92 respectively) and in group II 
(2.25 ± 0.15, 4.01±0.57 , 4.12±0.56 respectively) and in group III  (0.57 ± 0.13, 
2.15±0.14 and 0.00) were compared and difference was highly significant. 
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                        The present study showed significantly higher level of serum Cystatin 
C in group I    ( 995.56 ± 68.17) and Group II(1198.9 ± 31.51) as compared to Group 
III(737.6 ± 24.6 ) at baseline level. The results of present study indicate a significant 
correlation between plaque index, PPD, CAL and Cystatin C which is consistent with 
the findings of   Graziani et al  who observed statistically significant increase in 
Cystatin C levels in  subjects with periodontal disease and a positive correlation 
between elevated levels of Cystatin C and plaque index, PPD and CAL .
66
  
                       It was found that the baseline Cystatin C level in GCP and GAP were 
995.56 ng/ml and 1198.9 ng /ml respectively and in healthy control group at 737.6 
ng/ml which is in accordance with the study conducted by Anuj Sharma et al who 
detected that Cystatin C levels were significantly increased in serum of  Generalised 
Chronic periodontitis patients with Cystatin C Levels at 1143 ng/ml  versus 778 ng/ml 
in healthy controls .
5
 
                     After performing phase 1 therapy in all the patients, significant reduction 
was found in serum Cystatin C levels in chronic periodontitis and aggressive 
periodontitis patients (897.2 ± 56.19 & 939.9 ± 44.68  respectively) when compared 
to their baseline levels. This was in accordance with work done by Graziani et al 
who found that systemically healthy subjects suffering from severe generalized 
periodontitis had higher Cystatin  C  associated with some alteration in kidney 
function  and after receiving non-surgical periodontal therapy,decreased the 
inflammatory level and improved  kindney function significantly.  They considered 
that the inflammatory markers from periodontal disease may trigger a systemic acute-
phase systemic inflammatory response, characterized by increased levels of acute 
phase proteins which affect renal function. Non surgical periodontal therapy of such 
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patients can lead to reduction of systemic inflammation and improve renal 
functionality assessed by measuring GFR with CSTC 
66
  .                  
                     The mean CSTC levels in serum increased progressively from health to 
chronic and  aggressive  periodontitis .This result  were similar to study reported by  
Anuj sharma et al  and substantiate the association between serum CSTC  level and 
severity of periodontitis . Reason can be the inflammatory cytokines associated with 
periodontitis which stimulate the production of lysosomal  cathepsins, and increased 
plasma concentrations of Cystatin C, a cathepsin inhibitor,may reflect, at least in part, 
an attempt to counterbalance a potentially damaging increased osteoclastic activity 
5
. 
                   The mean serum  CSTC levels  decreased in  chronic and  aggressive  
periodontitis    subjects  after non surgical therapy,  reason may be  production of 
CSTC increases in local periodontal tissue as a protective marker and spill over from 
local tissue to serum leads to elevation of serum CSTC in transformation from 
periodontal health to disease, and after non surgical periodontal therapy, local 
inflammatory component subsided, reduction in CSTC levels takes place in 
periodontal tissues and so in serum. 
                       The mean serum Cystatin C concentration significantly increased in 
aggressive form of periodontitis.  The possible reason could be CSTC has a regulatory 
role in inflammatory process by down regulating phagocytic activity of neutrophil  
which  leads to increased destruction of periodontal tissues as demonstrated by 
Leung-Tack et al. 
52.
 
                      In various other chronic inflammatory diseases, increase in serum 
concentration of CSTC has been detected.  Leung et al 1990 reported that high CSTC 
concentrations are directly related to both inflammation and atherosclerosis and 
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involved in the pathogenesis of atherosclerosis.
43
 Bartova et al 2014  reported 
periodontitis as a risk factor of atherosclerosis.
98
 
                      Kestenbaum et al.  evaluated that for each 15 nmol/L (0.2 mg/L) 
increase in CSTC concentration there was a 15% greater incidence of hypertension 
44
. 
So elevated serum CSTC levels due to periodontal disease can increase the risk of 
cardiac diseases.                             
                       Within  the limitations of the present study,  it can be concluded  that  
serum CSTC concentration was found to be elevated from periodontal healthy group 
to chronic periodontitis  and aggressive periodontitis group  and decreased after 
instituting non surgical phase 1 therapy . This suggests that CSTC acts as anti-
inflammatory marker in  serum. 
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                                              SUMMARY AND CONCLUSION  
 
                       The present study was conducted in order to evaluate serum Cystatin C 
level in chronic and aggressive periodontitis patients before & after phase 1 therapy . 
                    A total of 30 patients were selected; 10 each of chronic periodontitis, 
aggressive periodontitis and non-periodontitis and were divided into three groups. 
The clinical and laboratory data were assessed at baseline and at 3 months after phase 
1 therapy and the values were subjected to statistical analysis.  
The following conclusions were drawn from the study:  
than healthy  
gressive periodontitis patients, serum Cystatin  C  level is slightly  raised than  
chronic  periodontitis.  
py in  group 1 and group II , serum Cystatin C 
levels show appreciable reduction in chronic and aggressive periodontitis .  
                    Within the  limitation  of the  present study,  it can be concluded  that  
serum  CSTC acts as anti-inflammatory marker in serum. The role of CSTC as an 
“inhibitory  biomarker of osteoclastic activity” can be explored in future as a 
potential therapeutic target in the treatment of periodontal disease.  
                     Further, longitudinal prospective studies involving larger population are 
needed to confirm the findings of present study and to better understand the role of 
CSTC in the pathogenesis of periodontal diseases. 
. 
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Annexure 1 
PARTICIPANT INFORMATION SHEET 
TITLE OF THE STUDY: 
“Evaluation  of Serum  cystatin c levels in aggressive and chronic periodontitis  before 
and after phase I therapy ..  
NAME OF THE RESEARCH INSTITUTION: 
Tamil Nadu Government Dental College and Hospital, Chennai. 
PURPOSE OF THE STUDY: 
The purpose of this study is to Evaluate  of Serum  cystatin c levels in aggressive and 
chronic periodontitis  before and after phase I therapy . 
PROCEDURE: 
 Case history, Intra Oral examination X rays will be taken. About  one teaspoon  of  
blood will be drawn from your hand. Scaling (cleaning of the teeth surface) and root planning 
will be done under Local anaesthesia. For some of the   participants the blood sample will be 
collected after 3months once againcollected blood will be sent for estimation of serum 
cystatinc  level. Clinical parameters such as gingival bleeding index, plaque index, probing  
pocket depth and clinical attachment level will be done. 
RISK OF PARTICIPATION: 
 Pain, swelling can happen during blood sample collection.  
Radiation exposure during IOPA view radiographs procedure 
Pain and discomfort due to local anaesthetic effect 
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BENEFITS OF PARTICIPATION: 
 Patients get scaling and root planning therapy for periodontal disease. 
CONFIDENTIALITY: 
 The identity of the patients participating in the research will be kept confidential 
throughout the study. In the event of any publication and presentation resulting from the 
research, no personally identifiable information will be shared. 
PARTICIPANTS RIGHTS: 
 Taking part in the study is voluntary. You are free to decide whether to participate in 
the study or to withdraw at any time. Your decision will not result in any loss of benefits to 
which you are otherwise entitled. 
COMPENSATION :  Nil 
 
 
Name of the participant    Signature of the  participant 
 
 
 
 
For queries related to study: For queries related to rights of  participant: 
 
XXXXXXXXXXX                                                      XXXXXXXXXXX 
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Annexure 2 
                                      INFORMED CONSENT FORM 
EVALUATION  OF SERUM  CYSTATIN C LEVELS IN AGGRESSIVE AND 
CHRONIC PERIODONTITIS  BEFORE AND AFTER PHASE I THERAPY ..  
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been answered to 
my satisfaction. I consent voluntarily to participate as a participant in this study and 
understand that I have the right to withdraw from the study at any time without in any way it 
affecting my further medical care.” 
 
 ________________        __________________________         ________________________ 
           Date   Name of the participant         Signature/Thumb impression 
         of the participant 
 
[The literate witness selected by the participant must sign the informed consent form. The 
witness should not have any relationship with the research team; If the participant does not 
want to disclose his/her participation details to others, in view of respecting the wishes of the 
participant, he/she can be allowed to waive from the witness procedure. (This is applicable to 
literate participant ONLY). This should be documented by the study staff by getting signature 
from the prospective participant.] 
 
 
“I have witnessed the accurate reading of the consent form to the potential participant 
and the individual has had opportunity to ask questions. I confirm that the individual has 
given consent freely.” 
 
________________        __________________________          ________________________ 
           Date   Name of the witness            Signature of the witness 
________________        __________________________          ________________________ 
 
      Date       Name of the interviewer                        Signature of the Interviewer 
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Annexure 3: Participant Information Sheet: Tamil  
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                    XXXXXXXXXX 
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Annexure 4: Informed Consent Form: Tamil
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ANNEXURE 5 
DEPARTMENT OF PERIODONTICS 
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL 
CHENNAI – 600 003 
EVALUATION  OF SERUM  CYSTATIN C LEVELS IN AGGRESSIVE 
AND CHRONIC PERIODONTITIS  BEFORE AND AFTER PHASE I 
THERAPY ..  
PROFORMA 
OP No:     DATE: 
NAME:     PATIENT ID No:    
AGE/SEX: 
ADDRESS:      
MOBILE No: 
OCCUPATION:     
INCOME: 
CHIEF COMPLAINT: 
HISTORY OF PERSENTING ILLNESS: 
 
                                                                                                                            ANNEXURES 
 
86 
 
PAST MEDICAL HISTORY: 
 
PAST DENTAL HISTORY: 
 
HISTORY OF HABITS: 
 
INTRA ORAL EXAMINATION: 
1) No. of teeth present: 
2) Gingival examination 
Colour 
Contour 
Consistency 
Texture 
Position 
Pigmentation  
 
Mobility : 
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Recession  
 
PLAQUE INDEX – SILNESS AND LOE (1964): 
 
Calculation:  
 
BASELINE  
 
Score:                                                                     Inference  
 
 
3 MONTHS 
 
Score:                                                                         Inference 
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GINGIVAL BLEEDING INDEX – AINAMO AND BAY (1975) 
 
Calculation  
 
BASELINE  
 
   Score:                                                                 Inference  
 
3 MONTHS  
 
  Score:                                                                      Inference 
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PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) (mm) 
 
MAXILLARY:                                                                  Buccal 
Palatal 
 
MANDIBULAR:                                                       Lingual 
Labial  
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INVESTIGATIONS 
Blood Investigation: 
Hb count 
Total Leucocyte count 
Differential Leucocyte count 
Bleeding Time 
Clotting Time 
Random Blood Sugar 
 
Serum  cystatin c  level 
SAMPLE BASELINE 3 MONTHS 
Serum  cystatin c 
  
 
 
DIAGNOSIS 
 
PROGNOSIS 
 
TREATMENT 
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Phase I: 
 
S.NO CALCULATIONS BASELINE 3 MONTHS 
1 Plaque index   
2 Gingival bleeding index   
3 Probing pocket depth   
4 Clinical attachment level   
5 Serum  cystatin c  level   
 
 
 
 
 
SIGNATURE OF PG STUDENT                                                SIGNATURE OF GUIDE 
 
DATE 
 
 
 
 
 
